Delcath Systems Inc DCTH

$15.67 +0.31 (2.02%)

Valuation

Market cap
532,977,000
Revenue TTM
$85,230,000
Net income TTM
$2,700,000
PE ratio
1,504.00
Forward PE
—
Profit margin
3.17%
Debt to equity
0.00

Trading

Volume
207,452
Avg volume
514,612
Day's range
$15.30 – $15.75
Shares out
34,699,000
Stochastic %K
56%
Beta
0.60
Analysts
Strong Sell
Price target
$25.00

Price

Company profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO...

Show more

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Industry
Medical Devices
Sector
Healthcare
Phone
212 489 2100
Website
https://www.delcath.com
Address
566 Queensbury Avenue, Queensbury, United States

Latest news

Stocktwits

brunoq14 Oct 8, 6:31 PM
$DCTH If this is going to fill the gap from the Q2 earnings rally, it would have to go to around 12.50, because the stock jumped from there to over 14.00.
0 replies
boohoooomillenials Oct 8, 12:01 PM
$DCTH the more they push this down before earnings in 20 days, the more i will buy. I think this is a runner to 25-30 in next 3-6 months
1 replies
brunoq14 Oct 6, 11:28 PM
$DCTH The current Estimated Primary Completion date for the Phase 2 MCC with Liver Cancer Dominant trial is December, 2026. Last update was June 1.
0 replies
Playthegame06 Oct 6, 4:53 PM
$DCTH Beware people…..the street wants to lull you into thinking $16 is the top. They want your shares so they can get ready for the next run to $25
0 replies
Polaris2024 Oct 1, 9:05 AM
$DCTH Remember my comments on Gerrard being conservative. If numbers come below second quarter price will be $14 to $15 range, if about the same as second quarter the price will be $17 to $19 range and if above second quarter will be $20 to $26 as all the analysts will be all over it and we know we got a winner. Let’s hope for at least the same as second quarter numbers.
0 replies
FrankZA Oct 1, 5:38 AM
$DCTH Q3 is done and we are waaaay back on the pace for new site activations. That combined with the possible seasonality because of summerholidays might create a disaster for Delcath Q3...or not :)
0 replies
Polaris2024 Sep 25, 12:56 AM
$DCTH I just want to remind you a comment I made after the last earnings call. Gerrard always underestimated their prediction, but last call for the first time upped his predictions on sales for the company over what was estimated. This will be big this next quarter and is just a start as this company gains momentum. The base is $16 now and next quarter $20 to $24 are my predictions.
0 replies
Polaris2024 Sep 23, 10:06 PM
$DCTH I agree with Wainwrights prediction unless there is a M & A that happens and if there is strong growth besides the breast cancer approval this estimate would be conservative.
1 replies